Xoma Royalty Corp（XOMA）资讯与事件XOMAXoma Royalty Corp

Stock Futures Muted as Oil Prices Rise

Stock futures are relatively muted to start the week as markets pause near record highs following a multi-week rally. Investors are balancing continued strength in corporate earnings and AI-driven optimism with rising geopolitical tension and macro uncertainty.The collapse of U.S-Iran peace talks has pushed oil prices higher, with crude climbing toward the mid-$90s to above $100 range, raising fresh concerns about inflation and global growth. Energy markets are reacting sharply to disruptions around the Strait of Hormuz.More than 80% of S&P 500 companies reporting so far have beaten earnings expectations, reinforcing the idea that fundamentals remain resilient. Chipmakers and large-cap tech continue to anchor the rally.Markets are bracing for earnings from major technology companies alongside a Federal Reserve meeting that could shape rate expectations for the second half of the year. While the Fed is widely expected to hold rates steady in the near term, investors are increasingly focused on forward guidance. Bond markets are signaling a possible inflection point. Treasury yields have been compressing into a tight range, with technical indicators suggesting a breakout could be imminent.In pre-market trading, S&P 500 futures fell 0.11%, Nasdaq futures fell 0.13% and Dow futures fell 0.14%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Oruka Therapeuticsup 31% after announcing interim results from its EVERLAST-A Phase 2a trial of ORKA-001Veradermicsup 22% after reporting its VDPHL01 trial met all primary and secondary endpointsQualcommup 9% after analyst Ming-Chi Kuo said on social media that industry checks show OpenAI is working with MediaTek and Qualcomm to develop smartphone processorsXomaup 6% and Ligandup 3%, respectively, after the companies entered into a definitive agreement under which Ligand will acquire Xoma Royalty for $39 per share of common stock in cashUP AFTER EARNINGS -Verizonup 2%DOWN AFTER EARNINGS -Domino's Pizzadown 7%LOWER -Compass Therapeuticsdown 72% after reporting additional COMPANION-002 study resultsCampbell'sdown 2% after Bernstein downgraded shares to Market Perform with a price target of $21, down from $27Adobedown 1% after Mizuho downgraded the stock to Neutral with a price target of $270, down from $315

Ligand to Acquire Xoma Royalty for $39 per Share

Ligand (LGND) and Xoma (XOMA) announced that the companies have entered into a definitive agreement under which Ligand will acquire Xoma Royalty for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. Xoma Royalty stockholders are expected to separately receive one non-transferable contingent value right, or CVR, per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending litigation at Xoma Royalty. The cash purchase price at close represents an approximately 14% premium to Xoma Royalty's 30 trading day volume weighted average price as of April 24, the last trading day prior to announcement of the transaction. With this agreement, Ligand adds over 120 commercial, clinical, and preclinical stage assets to its royalty portfolio. Under the terms of the merger agreement, Ligand will acquire all the outstanding shares of common stock of Xoma Royalty for $39.00 per share in cash. The cash consideration for the transaction is expected to be funded with Ligand's existing cash on hand and borrowings under Ligand's existing credit facility. Xoma Royalty's Series X convertible preferred stock is expected to be converted into shares of common stock at its stated fixed price prior to closing, whereas the outstanding shares of Series A Preferred Stock and Series B preferred stock are expected to be redeemed. Xoma Royalty stockholders also will receive one CVR per share. The CVRs are intended to provide Xoma Royalty stockholders with the opportunity to receive certain net proceeds, if any are recovered, from certain ongoing litigation with regard to Xoma Royalty's dispute with Janssen Biotech regarding the commercialization of Tremfya. The transaction has been unanimously approved by the Ligand and Xoma Royalty boards of directors. Entities affiliated with BVF Partners, which own approximately 21% of the outstanding shares of Xoma Royalty common stock and approximately 44% assuming the conversion of their Series X convertible preferred stock, have agreed to convert such shares into shares of Xoma Royalty common stock prior to closing and have entered into a voting agreement in support of the transaction. In addition, Xoma Royalty's directors and officers have also entered into voting agreements in support of the transaction. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, approval by Xoma Royalty stockholders and the receipt of certain regulatory approvals.